ES2552320T3 - Nuevas piridín-2-onas y piridazín-3-onas sustituidas - Google Patents
Nuevas piridín-2-onas y piridazín-3-onas sustituidas Download PDFInfo
- Publication number
- ES2552320T3 ES2552320T3 ES09769133.1T ES09769133T ES2552320T3 ES 2552320 T3 ES2552320 T3 ES 2552320T3 ES 09769133 T ES09769133 T ES 09769133T ES 2552320 T3 ES2552320 T3 ES 2552320T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- halogen
- alkoxy
- hydroxy
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Abstract
Compuesto según la fórmula III o IV:**Fórmula** en las que: R es H, -R1, -R1-R2-R3 , -R1-R3 o -R2-R3; en el que R1 es arilo, heteroarilo, cicloalquilo o heterocicloalquilo, y se sustituye opcionalmente con R1', en el que R1' es alquilo C1-6, hidroxi, hidroxialquilo C1-6, alcoxi C1-6, halógeno, nitro, amino, cicloalquilo, heterocicloalquilo, ciano o haloalquilo C1-6, R2 es -C(>=O), -C(>=O)O, -C(>=O)N(R2'), -(CH2)q o -S(>=O)2; en el que R2' es H o alquilo C1-6; y q es 1, 2 o 3, R3 es H o R4; en el que R4 es alquilo C1-6, alcoxi C1-6, heteroalquilo C1-6, arilo, ariloalquilo, alquiloarilo, heteroarilo, alquilheteroarilo, heteroaril-alquilo, cicloalquilo, alquil-cicloalquilo, cicloalquil-alquilo, heterocicloalquilo, alquil-heterocicloalquilo o heterocicloalquil-alquilo, y se sustituye opcionalmente con uno o más de entre alquilo C1-6, hidroxi, oxo, hidroxialquilo C1-6, alcoxi C1-6, halógeno, nitro, amino, ciano, alquilsulfonilo C1-6 o haloalquilo C1-6, X es CH o N, Y1 es H o alquilo C1-6, Y2 es Y2a o Y2b, en el que Y2a es H o halógeno, e Y2b es alquilo C1-6, sustituido opcionalmente con uno o más Y2b', e Y2b' es hidroxi, alcoxi C1-6 o halógeno, cada Y2' es, independientemente, Y2'a o Y2'b, en el que Y2'a es halógeno, e Y2'b es alquilo C1-6, sustituido opcionalmente con uno o más Y2'b', e Y2'b' es hidroxi, alcoxi C1-6 o halógeno, n es 0, 1, 2 ó 3, Y3 es H, halógeno o alquilo C1-6,en el que alquilo C1-6 se encuentra sustituido opcionalmente con uno o más sustituyentes seleccionados de entre el grupo que consiste de hidroxi, alcoxi C1-6, amino y halógeno, m es 0 ó 1; Y4 es Y4a, Y4b, Y4c o Y4d, en el que Y4a es H o halógeno, Y4b es alquilo C1-6, sustituido opcionalmente con uno o más sustituyentes seleccionados de entre el grupo que consiste de haloalquilo C1-6, halógeno, hidroxi, amino, ciano y alcoxi C1-6, Y4c es cicloalquilo C3-7, sustituido opcionalmente con uno o más sustituyentes seleccionados de entre el grupo que consiste de alquilo C1-6, haloalquilo C1-6, halógeno, hidroxi, amino y alcoxi C1-6, y Y4d es amino, sustituido opcionalmente con uno o más alquilos C1-6, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7527708P | 2008-06-24 | 2008-06-24 | |
US75277P | 2008-06-24 | ||
PCT/EP2009/057320 WO2009156284A1 (en) | 2008-06-24 | 2009-06-15 | Novel substituted pyridin-2-ones and pyridazin-3-ones |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2552320T3 true ES2552320T3 (es) | 2015-11-27 |
Family
ID=40972952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09769133.1T Active ES2552320T3 (es) | 2008-06-24 | 2009-06-15 | Nuevas piridín-2-onas y piridazín-3-onas sustituidas |
Country Status (25)
Country | Link |
---|---|
US (4) | US7902194B2 (es) |
EP (1) | EP2297142B1 (es) |
JP (1) | JP5536049B2 (es) |
KR (1) | KR101299867B1 (es) |
CN (3) | CN103408533B (es) |
AR (1) | AR072272A1 (es) |
AU (1) | AU2009264400B2 (es) |
BR (1) | BRPI0914657A2 (es) |
CA (1) | CA2728016C (es) |
CL (1) | CL2010001483A1 (es) |
CO (1) | CO6382183A2 (es) |
CR (1) | CR11815A (es) |
EC (1) | ECSP10010709A (es) |
ES (1) | ES2552320T3 (es) |
HK (2) | HK1152940A1 (es) |
IL (1) | IL209141A0 (es) |
MA (1) | MA32487B1 (es) |
MX (1) | MX2010013191A (es) |
NZ (2) | NZ601700A (es) |
PE (1) | PE20100851A1 (es) |
RU (1) | RU2500680C2 (es) |
TW (1) | TWI396537B (es) |
UA (1) | UA103327C2 (es) |
WO (1) | WO2009156284A1 (es) |
ZA (1) | ZA201007816B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
DK2300459T3 (da) * | 2008-07-02 | 2013-09-02 | Hoffmann La Roche | Nye fenylpyrazinoner som kinasehæmmere |
US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
CA2748414A1 (en) * | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
MY160349A (en) * | 2010-05-07 | 2017-02-28 | Gilead Connecticut Inc | Pyridone and aza-pyridone compounds and methods of use |
AR082590A1 (es) * | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
JP5842004B2 (ja) * | 2010-09-01 | 2016-01-13 | ジーアイリード コネチカット インコーポレーテッドGilead Connecticut,Inc. | ピリダジノン、その製造方法及びその使用方法 |
TW201311669A (zh) | 2011-08-17 | 2013-03-16 | Hoffmann La Roche | 布魯頓氏酪胺酸激酶(bruton’s tyrosine kinase)之抑制劑 |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
AR088643A1 (es) * | 2011-11-03 | 2014-06-25 | Genentech Inc | Compuestos de 8-fluoroftalazin-1(2h)-ona |
MX2014005285A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos biciclicos de piperazina. |
EP2773639B1 (en) | 2011-11-03 | 2017-04-26 | F. Hoffmann-La Roche AG | Alkylated piperazine compounds as inhibitors of btk activity |
CA2854603A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
AU2013293087B2 (en) | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
GEP201706748B (en) | 2012-08-10 | 2017-10-10 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
RU2015111133A (ru) * | 2012-09-13 | 2016-11-10 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
WO2014076104A1 (en) * | 2012-11-16 | 2014-05-22 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
JP6089124B2 (ja) | 2013-03-05 | 2017-03-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトン型チロシンキナーゼの阻害薬 |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
CN110698481B (zh) * | 2013-07-03 | 2023-02-28 | 豪夫迈·罗氏有限公司 | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 |
CN105764502A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群及其类似物及衍生物的治疗益处的组合方法 |
EA201690127A1 (ru) | 2013-07-30 | 2016-07-29 | Джилид Коннектикут, Инк. | Состав на основе ингибиторов syk |
NZ715776A (en) | 2013-07-30 | 2017-04-28 | Gilead Connecticut Inc | Polymorph of syk inhibitors |
WO2015082583A1 (en) | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
EP3080099B1 (en) * | 2013-12-13 | 2018-04-11 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
EP3402789B1 (en) * | 2016-01-13 | 2020-03-18 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
AU2017240609B2 (en) | 2016-03-31 | 2021-07-15 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
JP2019529419A (ja) | 2016-09-19 | 2019-10-17 | エムイーアイ ファーマ,インク. | 併用療法 |
CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
WO2020172431A1 (en) | 2019-02-22 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1070056T1 (en) * | 1998-03-14 | 2004-12-31 | Altana Pharma Ag | Phthalazinone pde iii/iv inhibitors |
CN1636005A (zh) * | 1999-06-03 | 2005-07-06 | 克诺尔股份有限公司 | 苯并噻嗪酮和苯并噁嗪酮化合物 |
DZ3223A1 (fr) * | 1999-10-19 | 2001-04-26 | Merck & Co Inc | Inhibiteurs de tyrosine kinases |
AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
CN101223141A (zh) * | 2005-03-10 | 2008-07-16 | Cgi药品股份有限公司 | 特定取代的酰胺,其制备方法和使用方法 |
WO2006124731A2 (en) | 2005-05-12 | 2006-11-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
AU2006279992A1 (en) | 2005-08-09 | 2007-02-22 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2007027528A2 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-.receptor tyrosine kinases |
CA2620352A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
ATE548363T1 (de) * | 2005-08-29 | 2012-03-15 | Vertex Pharma | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen |
CN101405001A (zh) * | 2006-03-20 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 抑制btk和syk蛋白质激酶的方法 |
RU2008149245A (ru) * | 2006-05-15 | 2010-06-20 | Айрм Ллк (Bm) | Композиции и способы ингибирования рецепторных киназ fgf |
PE20080839A1 (es) | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
US7838523B2 (en) * | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ,インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
AR063707A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. |
CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
CA2701275C (en) * | 2007-10-23 | 2016-06-21 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
WO2009077334A1 (en) | 2007-12-14 | 2009-06-25 | F. Hoffmann-La Roche Ag | Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives |
NZ586916A (en) | 2008-02-05 | 2012-06-29 | Hoffmann La Roche | Novel pyridinones and pyridazinones |
US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
-
2009
- 2009-06-15 PE PE2010001046A patent/PE20100851A1/es not_active Application Discontinuation
- 2009-06-15 EP EP09769133.1A patent/EP2297142B1/en active Active
- 2009-06-15 NZ NZ601700A patent/NZ601700A/xx not_active IP Right Cessation
- 2009-06-15 KR KR1020107029040A patent/KR101299867B1/ko not_active IP Right Cessation
- 2009-06-15 UA UAA201100578A patent/UA103327C2/ru unknown
- 2009-06-15 CN CN201310343743.4A patent/CN103408533B/zh not_active Expired - Fee Related
- 2009-06-15 NZ NZ588819A patent/NZ588819A/xx not_active IP Right Cessation
- 2009-06-15 MX MX2010013191A patent/MX2010013191A/es active IP Right Grant
- 2009-06-15 JP JP2011514004A patent/JP5536049B2/ja not_active Expired - Fee Related
- 2009-06-15 AU AU2009264400A patent/AU2009264400B2/en not_active Expired - Fee Related
- 2009-06-15 CN CN201310740898.1A patent/CN103709148B/zh not_active Expired - Fee Related
- 2009-06-15 BR BRPI0914657A patent/BRPI0914657A2/pt not_active IP Right Cessation
- 2009-06-15 WO PCT/EP2009/057320 patent/WO2009156284A1/en active Application Filing
- 2009-06-15 CN CN200980123734.6A patent/CN102066366B/zh not_active Expired - Fee Related
- 2009-06-15 CA CA2728016A patent/CA2728016C/en not_active Expired - Fee Related
- 2009-06-15 RU RU2011101774/04A patent/RU2500680C2/ru not_active IP Right Cessation
- 2009-06-15 ES ES09769133.1T patent/ES2552320T3/es active Active
- 2009-06-22 AR ARP090102276A patent/AR072272A1/es not_active Application Discontinuation
- 2009-06-23 TW TW098121074A patent/TWI396537B/zh not_active IP Right Cessation
- 2009-06-24 US US12/456,911 patent/US7902194B2/en not_active Expired - Fee Related
-
2010
- 2010-10-25 CO CO10132213A patent/CO6382183A2/es active IP Right Grant
- 2010-11-01 ZA ZA2010/07816A patent/ZA201007816B/en unknown
- 2010-11-04 IL IL209141A patent/IL209141A0/en unknown
- 2010-11-25 CR CR11815A patent/CR11815A/es not_active Application Discontinuation
- 2010-12-20 CL CL2010001483A patent/CL2010001483A1/es unknown
- 2010-12-23 EC EC2010010709A patent/ECSP10010709A/es unknown
-
2011
- 2011-01-10 US US12/987,187 patent/US8124604B2/en not_active Expired - Fee Related
- 2011-01-18 MA MA33534A patent/MA32487B1/fr unknown
- 2011-07-08 HK HK11107060.7A patent/HK1152940A1/xx not_active IP Right Cessation
-
2012
- 2012-01-26 US US13/358,557 patent/US8618098B2/en not_active Expired - Fee Related
-
2013
- 2013-09-11 US US14/024,354 patent/US8822457B2/en not_active Expired - Fee Related
-
2014
- 2014-09-29 HK HK14109767.6A patent/HK1196358A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2552320T3 (es) | Nuevas piridín-2-onas y piridazín-3-onas sustituidas | |
CO6290767A2 (es) | Nuevos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-0na como moduladores de la actividad de la btk | |
AR072545A1 (es) | Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
AR059136A1 (es) | Derivados de indol-3-il-carbonil-espiro-piperidina | |
PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
AR052915A1 (es) | Derivados de pirrolidin y piperidin acetileno | |
PE20080318A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
ES2297727T3 (es) | Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos. | |
AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
DOP2011000061A (es) | Compuestos de pirrol | |
AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
PE20060977A1 (es) | Derivados de piperidinilo como bloqueantes de canales de calcio | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
CO5580762A2 (es) | Analogos de lipoxina a4 | |
ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
CO5700768A2 (es) | Derivados de benzoxazina y sus usos | |
AR064626A1 (es) | Sintesis de compuestos de pirrolidina | |
CO5570702A2 (es) | N-sulfonilo-4-metileneamino-3-hidroxilo-2-piridonas como agente antimicrobiano | |
CO5650235A2 (es) | Derivados de imidazol | |
AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
ECSP11011164A (es) | Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica | |
AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos |